Search

Displaying results 601 - 610 of 4246 in total
  1. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019

  2. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]

  3. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. … It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]

  4. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.

  5. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment

  6. Drug

    Mineral oil

    go.drugbank.com/drugs/DB11057
    ApprovedInvestigationalVet approved

    It is also used as a mild laxative for human or veterinary uses. … Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds

  7. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    This drug presented different dosages and it was administered as a capsule or suspension. … It was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.

  8. Drug

    Oxcarbazepine

    go.drugbank.com/drugs/DB00776
    ApprovedInvestigational

    - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. … [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood

  9. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective … Sofosbuvir is also available as a fixed dose combination product with [DB11613] as the commercially available product Epclusa.

  10. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is no longer available in the US market.